Kalytera Therapeutics will terminate its pre-clinical development programs in the treatment of bone disease. The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline. The terminated programs were evaluating three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture…